Lynx1 Capital Management LP Passage Bio, Inc. Transaction History

Lynx1 Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.86 - $1.73 $3.84 Million - $7.73 Million	4,466,712 Added 1178.06%	4,845,871 $6.54 Million
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.01 $113,421 - $190,925	189,035 Added 99.43%	379,159 $382,000
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.01 $644,964 - $986,991	-977,219 Reduced 83.71%	190,124 $125,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.19 $1.84 Million - $2.67 Million	-2,240,255 Reduced 65.74%	1,167,343 $1.1 Million
Q1 2023 May 15, 2023	BUY	$0.96 - $1.88 $49,613 - $97,160	51,681 Added 1.54%	3,407,598 $3.27 Million

Q4 2022 Feb 14, 2023	BUY	$1.06 - $1.48 $639,704 - $893,172	603,495 Added 21.93%	3,355,917 $4.63 Million
Q3 2022 Nov 14, 2022	BUY	$1.28 - $2.48 $2.98 Million - $5.78 Million	2,331,012 Added 553.15%	2,752,422 $3.44 Million
Q2 2022 Aug 15, 2022	BUY	$1.63 - $3.46 $514,926 - $1.09 Million	315,906 Added 299.43%	421,410 $995,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $280,640 - $684,720	105,504 New	105,504 $327,000

33M

20.3K

500

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $43M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.